Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Pipeline Assessment and Market Forecasts to 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, ""Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Assessment and Market Forecasts to 2017"". The report is an essential source of information and analysis on the global COPD market. The report identifies the key trends shaping and driving the global COPD market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global COPD sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData estimated the Chronic Obstructive Pulmonary Disease (COPD) market to be worth $8.4 billion in 2009 and projects it to grow at a Compound Annual Growth Rate (CAGR) of 4.7% to reach $12.2 billion in 2017. The development of novel once-daily inhaled therapies is expected to provide new treatment options for COPD patients worldwide, and will play a major role in the expansion of the COPD market in the coming years. A steady increase in the incidence rate, the smoking population and in injurious environmental factors in most countries has caused the COPD market to grow significantly.

Scope

The report provides information on the key drivers and challenges of the COPD market. Its scope includes:

• Annualized global COPD market revenues data from 2001 to 2009, forecast for eight years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as long-acting beta2 agonists, long-acting muscarinic antagonists, long-acting beta2 agonist and inhaled corticosteroid combinations, Inhaled Long-acting beta 2 Antogonist, PDE4 inhibitors and p38 kianse inhibitors.
• Analysis of the current and future competition in the global COPD market. Key market players covered are GSK, Almirall S.A., Novartis AG, AstraZeneca and Pfizer Inc.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the COPD therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global COPD market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global COPD market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What's the next big thing in the global COPD market landscape? - Identify, understand and capitalize.

Contents

• 1 Table of contents
  • 1.1 List of Tables
  • 1.2 List of Figures
• 2 Chronic Obstructive Pulmonary Disease Introduction
  • 2.1 GlobalData Pipeline Report Guidance
• 3 Chronic Obstructive Pulmonary Disease - Market Characterization
  • 3.1 Overview
  • 3.2 COPD Market Size
  • 3.3 COPD Market Forecast and CAGR
  • 3.4 Drivers and Barriers for the COPD Market
  • 3.4.1 Drivers for the COPD Market
  • 3.4.2 Barriers for the COPD Market
  • 3.5 Opportunity and Unmet Need
  • 3.6 Key Takeaway
• 4 Chronic Obstructive Pulmonary Disease Market : Competitive Assessment
  • 4.1 Overview
  • 4.2 Strategic Competitor Assessment
  • 4.3 Product Profile for the Major Marketed Products in the COPD Market
  • 4.3.1 Spiriva HandiHaler (Tiotropium bromide inhalation powder)
  • 4.3.2 Brovana (Arformoterol)
  • 4.3.3 Foradil Aerolizer (formoterol fumarate inhalation powder)
  • 4.3.4 Symbicort (budesonide/formoterol fumarate dihydrate) 160/4.5 µg
  • 4.3.5 Advair Diskus (fluticasone propionate and salmeterol inhalation powder)
  • 4.4 Key Takeaway
• 5 Chronic Obstructive Pulmonary Disease Market : Pipeline Assessment
  • 5.1 Overview
  • 5.2 Strategic Pipeline Assessment
  • 5.2.1 Technology Trends Analytic Framework
  • 5.3 COPD Therapeutics - Promising Drugs Under Clinical Development
  • 5.4 Molecule Profile for Promising Drugs Under Clinical Development
  • 5.4.1 Aclidinium Bromide
  • 5.4.2 Daxas (roflumilast)
  • 5.4.3 Indacaterol Maleate (QAB149, Onbrez Breezhaler)
  • 5.4.4 NVA237 (Glycopyrronium Bromide)
  • 5.5 COPD Market - Clinical Pipeline by Mechanism of Action
  • 5.6 COPD - Pipeline by Clinical Phases of Development
  • 5.6.1 COPD Therapeutics - Phase III Clinical Pipeline
  • 5.6.2 COPD Therapeutics - Phase II Clinical Pipeline
  • 5.6.3 COPD Therapeutics - Phase I Clinical Pipeline
  • 5.6.4 COPD Therapeutics - Pre-clinical Pipeline
  • 5.6.5 COPD Therapeutics - Discovery Pipeline
  • 5.7 Discontinued Drugs for COPD
  • 5.8 Key Takeaway
• 6 Chronic Obstructive Pulmonary Disease Market : Implications for Future Market Competition
• 7 Chronic Obstructive Pulmonary Disease Market : Future Players in the COPD Market
  • 7.1 Introduction
  • 7.2 GlaxoSmithKline plc
  • 7.2.1 Company Overview
  • 7.2.2 Respiratory Disease Portfolio
  • 7.3 Almirall S.A
  • 7.3.1 Company Overview
  • 7.3.2 Respiratory Disease Portfolio
  • 7.4 Novartis AG
  • 7.4.1 Company Overview
  • 7.4.2 Respiratory Disease Portfolio
  • 7.5 AstraZeneca
  • 7.5.1 Company Overview
  • 7.5.2 Respiratory Portfolio
  • 7.6 Pfizer Inc
  • 7.6.1 Company Overview
  • 7.6.2 Respiratory Disease Portfolio
• 8 Chronic Obstructive Pulmonary Disease Market : Appendix
  • 8.1 Market Definitions
  • 8.2 Abbreviations
  • 8.3 Research Methodology
  • 8.3.1 Coverage
  • 8.3.2 Secondary Research
  • 8.3.3 Forecasting
  • 8.3.4 Primary Research
  • 8.3.5 Expert Panels
  • 8.4 Contact Us
  • 8.5 Disclaimer
  • 8.6 Sources
• 1.1 List of Tables
  • Table 1: COPD Therapeutics Market, Global, Revenue ($bn), 2001-2009
  • Table 2: COPD Therapeutics Market, Global, Revenue ($bn), 2009-2017
  • Table 3: Major Marketed Products Comparison in COPD Market, 2010
  • Table 4: COPD Therapeutics - Most Promising Drugs Under Clinical Development, 2010
  • Table 5: COPD Therapeutics - Phase III Clinical Pipeline, 2010
  • Table 6: COPD Therapeutics - Phase II Clinical Pipeline, 2010
  • Table 7: COPD Therapeutics - Phase I Clinical Pipeline, 2010
  • Table 8: COPD Therapeutics - Pre-clinical Pipeline, 2010
  • Table 9: COPD Therapeutics - Discovery Pipeline, 2010
  • Table 10: List of Discontinued Drugs for COPD, 2010
  • Table 11: GlaxoSmithKline plc - Respiratory Disease Pipeline Products, 2010
  • Table 12: Almirall S.A- Respiratory Disease Pipeline Products, 2010
  • Table 13: Novartis AG- Respiratory Disease Pipeline Products, 2010
  • Table 14: AstraZeneca - Respiratory Marketed Products, 2010
  • Table 15: AstraZeneca - Respiratory Pipeline Products, 2010
  • Table 16: Pfizer Inc - Respiratory Disease Pipeline Products, 2010
• 1.2 List of Figures
  • Figure 1: COPD Therapeutics Market Revenue ($bn) 2001-2009
  • Figure 2: Opportunity and Unmet Need in the COPD Market, 2010
  • Figure 3: Strategic Competitor Assessment of the Major Marketed Products for COPD, 2010
  • Figure 4: Technology Trends Analytic Framework of the COPD Pipeline, 2010
  • Figure 5: Technology Trends Analytic Framework of the COPD Pipeline - Description, 2010
  • Figure 6: COPD Market - Clinical Pipeline by Mechanism of Action, 2010
  • Figure 7: COPD Pipeline by Phase of Clinical Development, 2010
  • Figure 8: Implications for Future Market Competition in the COPD Market, 2010
  • Figure 9: COPD Market - Clinical Pipeline by Company, 2010
  • Figure 10: GlobalData Market Forecasting Model

Related products

Obstructive Pulmonary Disease Global Clinical Trials Review Q1, 2011 Obstructive Pulmonary Disease Global Clinical Trials Review, Q1, 2011 Summary GlobalData's clinical trial report, "Obstructive Pulmonary Disease Global Clinical Trials Review, Q1, 2011" provides data on the Obstructive Pulmonary Disease clinical trial...

U.S. Asthma/COPD Market This research service provides an in depth analysis of factors affecting the growth of the U.S. asthma/COPD market over the period 2006-2016. Included is a disease overview, product analysis, total...

Chronic Obstructive Pulmonary Disease This report analyzes the worldwide markets for Chronic Obstructive Pulmonary Disease in US$ Million. The report provides separate comprehensive analytics for US and Rest of World. Annual forecasts are...

Epidemiology: COPD in India In 2010, almost 24 million adults over the age of 40 in India had COPD. Datamonitor expects this number to increase 34% to approximately 32 million by 2020. COPD is...

Market for Respiratory Equipment and Disposables 4th Edition, The The market for respiratory disposables and reusable accessories is currently witnessing dynamic changes, thus making it one of the most important device sectors. The market factors influencing demand are the...

The Respiratory Diagnostic Devices Market Outlook to 2016 Introduction This report covers the epidemiology of the key respiratory disorders forecasting this to 2016. The report then goes on to give in depth analysis of the major diagnostic technologies including:...

Respiratory Therapeutics and Devices Markets In the respiratory therapeutics and devices market, continuing new advancements in the ability to detect and manage respiratory diseases are being made. The respiratory disease space is one of the...

North American Home Health Care and Disease Management Markets for Remote Patient Monitoring This research service analyzes market trends in the North American home health care and disease management markets since 2005, predicts future changes in market measurements through 2015, and discusses specific...

World Respiratory Disorders Market 2009-2024 Expanding patent populations and rising disease prevalence - World Respiratory Disorders Market 2009-2024 shows you where the opportunities lie in respiratory disorders Respiratory disorder therapies form an important and competitive part...

Chronic Obstructive Pulmonary Disease (COPD) Market: An Analysis In the present era, use of tobacco, polluted environment, poverty and aging population have become a major threat; all these factors account for a major cause of deaths by COPD....

Pulmonary Drug Delivery Technologies This report analyzes the worldwide markets for Pulmonary Drug Delivery Technologies in US$ Million by the following Product Segments: Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), and Others. The...

Enzyme Inhibitors with Broad Therapeutic Applications The aim of this report is to provide a range of information-from detailed market analyses through industry trends-to quantify and qualify the market for therapeutic enzyme inhibitors with large markets...

The Future of Anesthesia and Respiratory Devices, Competitive Landscape and Forecasts to 2016 Home and Self Care Respiratory Devices Presenting Growth Avenues GBI Research's medical device report, 'The Future of Anesthesia and Respiratory Devices, Competitive Landscape and Forecasts to 2016 - Home and Self Care Respiratory Devices Presenting Growth Avenues' provides key...

Global Markets for Asthma and COPD Drugs Report Highlights Overall sales in the asthma and COPD drugs market were worth $25 billion in 2008, and increased to an estimated $26 billion in 2009. By 2014, it is projected...

Chronic Obstructive Pulmonary Disease Therapy Area Pipeline Report Life Science Analytics', Chronic Obstructive Pulmonary Disease Therapy Area Pipeline Report contains detailed information on the chronic obstructive pulmonary disease drug pipeline. This report provides insight into the pipeline status...

p38 MAPK Inhibitors Competitor Analysis Product description The present Competitive Intelligence Report about p38 MAPK inhibitors used to treat inflammatory diseases such as rheumatoid arthritis, psoriasis, COPD or pain, respectively, provides a competitor evaluation in the...

Tiotropium Bromide Comprehensive Patent Search Eliminate unnecessary risk with the industry benchmark in comprehensive patent information. Pipeline Developer is a regularly updated, professional patent search performed by our expert team, which not only identifies relevant patents,...

Elastase Inhibitors Competitor Analysis The present Competitive Intelligence Report about elastase inhibitors provides a competitor evaluation in the field of human plasma-derived, recombinant, transgenic, synthetic and gene therapeutic approaches for treatment of lung emphysema...

Therapeutics for Inflammatory Diseases: Current Challenges and Future Market The anti-inflammatory products market was dramatically shaken in September 2004 with the withdrawal from the marketplace of Merck's multibillion-dollar anti-inflammatory drug Vioxx. This was followed by the withdrawal of another...

Respiratory Devices Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 Summary GlobalData's new report, Respiratory Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 provides key data, information and analysis on the global respiratory devices market. The report...

The Future of Respiratory Diseases Therapeutics Market Forecasts to 2015 The Future of Respiratory Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis Summary GBI Research, the leading business intelligence provider, has released its latest research ""The...

View all products in this category